Loading organizations...
Key people at Cube Labs.
Cube Labs is a Rome, Italy-based venture builder that transforms academic life sciences research into scalable healthcare technology companies. Operating across the biomedical sector with an additional office in Lecce, the firm provides end-to-end operational support from technology scouting to commercial market access. The organization has launched 18 healthcare startups, secured over 60 patents, and successfully brought two distinct products to the commercial market. Cube Labs is publicly listed on the Euronext Growth Milan exchange and maintains strategic partnerships with entities like Modi Global Enterprises to expand into emerging global markets. The firm focuses on addressing unmet medical needs, recently spinning out a new company dedicated to chronic diabetes-related wound treatments. Advised by industry figures including Yossi Bornstein, Jeremy Curnock Cook, and Adina Krausz, the firm was founded by Filippo Surace, Renato Del Grosso, and Massimo Fiocchi.
Cube Labs S.p.A. (BIT:CUBE) is an Italy-based venture capital firm, accelerator, and venture builder specializing in incubation and early-stage investments in life sciences and healthcare technology.[1][2][3][4] Its mission centers on enabling innovation in healthcare by transforming promising R&D into startups, focusing on pharmaceuticals, biotech, nutraceuticals, R&D tech/AI, and medtech to accelerate the democratization of the life science sector and make research more accessible.[4] The firm emphasizes open innovation, sustainability aligned with UN 2030 Agenda goals, and strategic investments in cutting-edge technologies with commercial potential, backed by a network of universities, researchers, and offices in Rome and Lecce.[1][4]
Cube Labs impacts the startup ecosystem through hands-on incubation for biotech, pharma, and medtech SMEs, fostering collaboration and co-creation while listing publicly on Borsa Italiana for broader capital access.[1][3]
Founded by Filippo Surace (CEO and MD) alongside co-founders Renato Del Grosso (Chief Strategy Officer) and Massimo Fiocchi (CFO), Cube Labs emerged to bridge academic R&D with commercial healthcare ventures in Italy.[1][2] Based in Rome with an additional office in Lecce, the firm has evolved from a traditional VC/accelerator model to a full venture builder, scouting global technologies and incubating startups in high-potential life science areas.[1][4] Key early traction stems from building networks with over universities, researchers, and patents (specific figures highlighted on their site), supported by a strong advisory board including experts like Fintan Walton and Yoseph Bornstein.[2][4]
Cube Labs rides the wave of AI-driven drug discovery, personalized medtech, and biotech democratization, capitalizing on post-pandemic demand for accessible healthcare innovations amid aging populations and global R&D bottlenecks.[4] Timing is ideal in 2025, with Europe's life sciences sector booming via public markets and sustainability mandates, positioning Italy as a hub through Cube's Rome-Lecce base and cross-institutional networks.[1][4] Market forces like AI integration in pharma R&D and nutraceutical growth favor its portfolio, while the firm influences the ecosystem by lowering barriers to scientific tools, promoting co-creation, and scaling startups via public listing—amplifying impact beyond traditional VC silos.[3][4]
Cube Labs is poised to expand its venture builder pipeline amid surging AI/medtech investments, potentially launching more unicorns from its R&D tech focus as regulatory tailwinds (e.g., EU AI Act clarity) unlock biotech scaling.[4] Trends like precision medicine and sustainable health will shape its trajectory, evolving its influence from Italian incubator to pan-European player via deeper university ties and advisory firepower.[2][4] As a public entity, expect asset growth and portfolio exits, reinforcing its role in making elite life sciences accessible—turning pioneering science into global healthcare wins.[1][4]
Key people at Cube Labs.
